

between kidney structure and function, early molecular and structural predictors of diabetic kidney disease, and clinical trials studying repurposed and new drugs for the prevention and treatment of diabetic kidney disease. Dr. Caramori has authored more than 50 publications in peer-reviewed journals, and 18 book chapters. She has been funded by grants from the National Institutes of Health (NIH), JDRE, and the National Kidney Foundation (NKF) of Minnesota, among others. Currently, Dr. Caramori is the principal investigator of an NIH R01 grant to study protective factors in diabetic kidney disease.

Dr. Caramori was a member of the NKF Kidney Disease Outcomes Quality Initiative (KDOQI) Work Group and helped to develop the 2007 Clinical Practice Guidelines and Recommendations for Diabetes and CKD. Dr. Caramori is the past-chair of the diabetic nephropathy subcommittee for the ADA Scientific Sessions (2018–2020). She also volunteers her time to aid important initiatives of the JDRE, ADA, and American Society of Nephrology (ASN).

MLC reports consultancy fees from AstraZeneca, Bayer Pharmaceuticals, and Boehringer Ingelheim; grant support from Bayer Pharmaceuticals, Boehringer Ingelheim*, and Novartis; and speaker fees from Bayer Pharmaceuticals.*

**Monies paid to institution.*



Juliana C.N. Chan, MBChB, MD, FHKCP, FHKAM, FRCP, is chair professor of medicine and therapeutics and a director at the Hong Kong Institute of Diabetes and Obesity at the Chinese University of Hong Kong. She is a physician scientist specializing in diabetes and clinical pharmacology. In 1995, she developed a data-driven

integrated-care model to establish the Hong Kong Diabetes Register (HKDR) for individualizing care and monitoring outcomes, while the accompanying biobanks were used for genetic discovery in pursuit of precision medicine.

In 2000, this research-driven quality improvement program formed the template for a territory-wide risk assessment and management program, which contributed to a 50% to 70% decline in the death rate in people with diabetes in Hong Kong from 2000 to 2016, while creating a population-based diabetes database for knowledge discovery. In 2007, she designed the Joint Asia Diabetes Evaluation (JADE) Technology, which enables systematic data collection for risk stratification and personalized reporting with decision support to promote collaborative research in Asia.

Professor Chan has published over 500 peer-reviewed articles and 20 book chapters. She is a member of steering committees of international projects and outcome trials. In 2019, Professor Chan received the ADA Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes. In 2020, in collaboration with global experts, she led the Lancet Commission on Diabetes to advocate using data to transform diabetes care and patient lives.

JCNC reports board membership with Asia Diabetes Foundation; consultancy fees from AstraZeneca, Bayer Pharmaceuticals*, Boehringer Ingelheim*, Celltrion, Merck Sharp & Dohme*, Novartis*, Roche*, Sanofi*, and Viatris*; grant support from Applied Therapeutics*, AstraZeneca*, Eli Lilly and Company*, Hua Medicine*, Lee Powder*, Merck*, Pfizer*, and Servier*; speaker fees from AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim*, Merck*, Merck Sharp & Dohme*, Sanofi*, Viatris*; educational presentations for Boehringer Ingelheim*; being founding director and shareholder of startup biogenetic testing company GEMVCARE, with partial support by the Hong Kong government; and being co-inventor for the patent of biomarkers for predicting diabetes and its complications.*

**Monies paid to institution.*



Hiddo J.L. Heerspink, PhD, PharmD, is professor of clinical trials and personalized medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, The Netherlands. He is also a visiting professor at the University of New South Wales in Sydney,

Australia. He studied pharmacy at the University of Groningen and subsequently received his PhD from the University Medical Center Groningen. He worked as a postdoctoral fellow at The George Institute for Global Health, Sydney, Australia, where he investigated the effects of blood pressure-lowering regimens on renal and cardiovascular outcomes in patients with CKD.

Professor Lambers-Heerspink's research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of kidney and cardiovascular diseases in patients with diabetes, with a specific focus on personalized medicine. He leads and participates in clinical trials focused on kidney and cardiovascular complications of type 2 diabetes. His main expertise includes clinical trial design and personalized medicine, as well as methodological aspects and statistical analyses of clinical trials.

Professor Lambers-Heerspink has received grants from the Netherlands Organisation of Scientific Research, the Young Investigator Research Award from the European Foundation for the Study of Diabetes, the Harry Keen Award from the EASD, and several personal grants to develop novel strategies to improve the treatment for patients with type 2 diabetes and kidney complications. He is an editorial board member of the *Clinical Journal of the American Society of Nephrology* and served as guest editor for scientific journals including *Diabetes Obesity & Metabolism* and *Nephrology Dialysis Transplantation*. He has authored and coauthored over 350 peer-reviewed publications.

HJLH reports consultancy fees from Abbvie, AstraZeneca*, Bayer Pharmaceuticals*, Boehringer Ingelheim*, Chinook*, CSL Behring*, Dimerix, Gilead*, Goldfinch Bio, Janssen*, Merck & Co*, Mitsubishi Tanabe*, Mundipharma,*